Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,668 | 2 | 87.0% |
| Travel and Lodging | $1,048 | 6 | 7.2% |
| Food and Beverage | $837.64 | 19 | 5.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $14,373 | 22 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $104.21 | 2 | $0 (2018) |
| Astellas Pharma US Inc | $35.00 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $22.69 | 1 | $0 (2022) |
| Acrotech Biopharma Inc. | $18.08 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $53.08 | 2 | Astellas Pharma US Inc ($35.00) |
| 2022 | $22.69 | 1 | E.R. Squibb & Sons, L.L.C. ($22.69) |
| 2019 | $8,832 | 17 | Incyte Corporation ($8,832) |
| 2018 | $234.21 | 4 | Incyte Corporation ($130.00) |
| 2017 | $5,411 | 3 | Incyte Corporation ($5,411) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/06/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: ONCOLOGY | ||||||
| 02/21/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: Oncology | ||||||
| 03/08/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $22.69 | General |
| Category: Cardiovascular | ||||||
| 09/05/2019 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $60.00 | General |
| Category: Hematology/Oncology | ||||||
| 05/14/2019 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $7,380.00 | General |
| 04/26/2019 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $56.25 | General |
| 04/26/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 04/26/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $40.00 | General |
| 04/26/2019 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $24.00 | General |
| 04/26/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $23.35 | General |
| 04/26/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| 04/26/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| 04/25/2019 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $518.00 | General |
| 04/25/2019 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $249.91 | General |
| 04/25/2019 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 04/25/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| 04/25/2019 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $49.53 | General |
| 04/25/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| 04/25/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $12.20 | General |
| 04/17/2019 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $33.33 | General |
| Category: Hematology/Oncology | ||||||
| 12/03/2018 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $58.46 | General |
| 04/23/2018 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $45.75 | General |
| Category: Oncology | ||||||
| 03/21/2018 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $70.00 | General |
| Category: Hematology/Oncology | ||||||
| 01/18/2018 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $60.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/10/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $24.78 | General |
| Category: Hematology/Oncology | ||||||
About Kim-Hien Dao, DO, PHD
Kim-Hien Dao, DO, PHD is a Hematology healthcare provider based in Salem, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/25/2008. The National Provider Identifier (NPI) number assigned to this provider is 1770748121.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Kim-Hien Dao, DO, PHD has received a total of $14,553 in payments from pharmaceutical and medical device companies, with $53.08 received in 2024. These payments were reported across 27 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($12,668).
Practice Information
- Specialty Hematology
- Location Salem, OR
- Active Since 07/25/2008
- Last Updated 01/21/2021
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1770748121
Products in Payments
- JAKAFI (Drug) $5,635
- CALQUENCE (Drug) $45.75
- Xospata (Drug) $35.00
- ELIQUIS (Drug) $22.69
- BELEODAQ (Drug) $18.08
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.